Gomez-Roca C - Search Results

1

Clinical benefit for patients with non-small cell lung cancer enrolled in phase I trials.

Levy A, Gomez-Roca C, Massard C, Planchard D, Albiges L, Bahleda R, Bourgier C, Deutsch E, Soria JC, Besse B. Levy A, et al. Onkologie. 2013;36(6):357-62. doi: 10.1159/000351257. Epub 2013 May 13. Onkologie. 2013. PMID: 23774150 Clinical Trial.

2

Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.

Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L, Sabatier L, Dartevelle P, Taranchon E, Besse B, Validire P, Italiano A, Soria JC. Gomez-Roca C, et al. J Thorac Oncol. 2009 Oct;4(10):1212-20. doi: 10.1097/JTO.0b013e3181b44321. J Thorac Oncol. 2009. PMID: 19687761 Free article.

3

Pemetrexed-induced pneumonitis: a case report.

Loriot Y, Ferte C, Gomez-Roca C, Moldovan C, Bahleda R, Wislez M, Cadranel J, Soria JC. Loriot Y, et al. Clin Lung Cancer. 2009 Sep;10(5):364-6. doi: 10.3816/CLC.2009.n.050. Clin Lung Cancer. 2009. PMID: 19808196

4

Rhinitis in patients treated with a combination of an mTOR inhibitor and an EGFR inhibitor.

Prulière-Escabasse V, Gomez-Roca C, Escudier E, Coste A, Besse B, Massard C, Soria JC. Prulière-Escabasse V, et al. Onkologie. 2010;33(7):401-2. doi: 10.1159/000315757. Epub 2010 Jun 22. Onkologie. 2010. PMID: 20631489 No abstract available.

5

Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?

Postel-Vinay S, Gomez-Roca C, Molife LR, Anghan B, Levy A, Judson I, De Bono J, Soria JC, Kaye S, Paoletti X. Postel-Vinay S, et al. J Clin Oncol. 2011 May 1;29(13):1728-35. doi: 10.1200/JCO.2010.31.9236. Epub 2011 Mar 28. J Clin Oncol. 2011. PMID: 21444876

6

Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues.

Ferté C, Paci A, Zizi M, Gonzales DB, Goubar A, Gomez-Roca C, Massard C, Sahmoud T, André F, Soria JC. Ferté C, et al. Eur J Cancer. 2011 Oct;47(15):2249-55. doi: 10.1016/j.ejca.2011.03.017. Epub 2011 Apr 12. Eur J Cancer. 2011. PMID: 21489779 Clinical Trial.

7

Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials.

Levy A, Albiges-Sauvin L, Massard C, Izzedine H, Ederhy S, Bahleda R, Gomez-Roca C, Chargari C, Brocheriou-Spelle I, Soria JC. Levy A, et al. Invest New Drugs. 2012 Jun;30(3):1116-20. doi: 10.1007/s10637-011-9671-z. Epub 2011 Apr 21. Invest New Drugs. 2012. PMID: 21509469 Clinical Trial.

8

Tumour growth rates and RECIST criteria in early drug development.

Gomez-Roca C, Koscielny S, Ribrag V, Dromain C, Marzouk I, Bidault F, Bahleda R, Ferté C, Massard C, Soria JC. Gomez-Roca C, et al. Eur J Cancer. 2011 Nov;47(17):2512-6. doi: 10.1016/j.ejca.2011.06.012. Epub 2011 Jul 15. Eur J Cancer. 2011. PMID: 21763126

9

Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety.

Gomez-Roca CA, Lacroix L, Massard C, De Baere T, Deschamps F, Pramod R, Bahleda R, Deutsch E, Bourgier C, Angevin E, Lazar V, Ribrag V, Koscielny S, Chami L, Lassau N, Dromain C, Robert C, Routier E, Armand JP, Soria JC. Gomez-Roca CA, et al. Ann Oncol. 2012 May;23(5):1301-1306. doi: 10.1093/annonc/mdr383. Epub 2011 Sep 14. Ann Oncol. 2012. PMID: 21917737 Free article.

10

Prognostic value of circulating VEGFR2+ bone marrow-derived progenitor cells in patients with advanced cancer.

Massard C, Borget I, Le Deley MC, Taylor M, Gomez-Roca C, Soria JC, Farace F. Massard C, et al. Eur J Cancer. 2012 Jun;48(9):1354-62. doi: 10.1016/j.ejca.2012.01.021. Epub 2012 Feb 25. Eur J Cancer. 2012. PMID: 22370181

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

87 results

Search Page